Post-Market Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (CF-EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation

Post-Market Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (CF-EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation

The purpose of this study is to confirm the safety and effectiveness of the CardioFocus Endoscopic Ablation System with Adaptive Contact in the treatment of atrial fibrillation.

Inclusion Criteria:

• Symptomatic, Paroxysmal Atrial Fibrillation (AF)
• 18 to 70 Years of age
• Others

Exclusion Criteria:

• Generally good overall health as determined by multiple criteria
• Willing to participate in a study
• Others